Equity Profile

NBIX

Neurocrine Biosciences, Inc.

Health CareBiotechnology$15.3B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

$1.96

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$890M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $15 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in these specialized areas.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1-2026, Neurocrine reported an EPS of $1.94, significantly beating estimates by 51.21%. The stock reacted positively, gaining 0.74% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing key neurological disorders.
Plans to enhance market presence and patient access.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Neurocrine's upcoming earnings, expecting solid performance based on historical trends.

Bull Case

If the company continues its track record of beating EPS estimates, it could see a strong positive reaction from investors, especially if revenue exceeds expectations.

Bear Case

On the other hand, any signs of slowing growth or failure to meet revenue targets could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.96

Earnings per share is a key indicator of profitability and can influence investor sentiment.

Revenue

$890M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.96?

Given the company's history of beating EPS estimates, this will be a critical measure of ongoing performance.

What is the revenue outlook compared to the consensus of $890M?

Revenue growth is essential for sustaining investor confidence and validating the company's growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Neurocrine to exceed revenue expectations due to strong demand for its existing products.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant reaction.

Recent product launches have shown promising uptake in the market.

Key Risk

If revenue comes in below $850M, it could raise concerns about the sustainability of growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Neurocrine can maintain its growth trajectory amid increasing competition in the biotech sector.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.80 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a move of about 3.8%, indicating some uncertainty ahead of the earnings report.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by around 2.03%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data suggesting a potential drop of around 2.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Insights into market demand for existing therapies.
3Management's outlook on competitive pressures.
4Details on patient access initiatives.
5Comments on cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

$1.96

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$890M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1-2026, Neurocrine reported an EPS of $1.94, significantly beating estimates by 51.21%. The stock reacted positively, gaining 0.74% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing key neurological disorders.
Plans to enhance market presence and patient access.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Neurocrine's upcoming earnings, expecting solid performance based on historical trends.

Bull Case

If the company continues its track record of beating EPS estimates, it could see a strong positive reaction from investors, especially if revenue exceeds expectations.

Bear Case

On the other hand, any signs of slowing growth or failure to meet revenue targets could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.96

Earnings per share is a key indicator of profitability and can influence investor sentiment.

Revenue

$890M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.96?

Given the company's history of beating EPS estimates, this will be a critical measure of ongoing performance.

What is the revenue outlook compared to the consensus of $890M?

Revenue growth is essential for sustaining investor confidence and validating the company's growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Neurocrine to exceed revenue expectations due to strong demand for its existing products.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant reaction.

Recent product launches have shown promising uptake in the market.

Key Risk

If revenue comes in below $850M, it could raise concerns about the sustainability of growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Neurocrine can maintain its growth trajectory amid increasing competition in the biotech sector.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.80 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a move of about 3.8%, indicating some uncertainty ahead of the earnings report.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by around 2.03%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data suggesting a potential drop of around 2.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Insights into market demand for existing therapies.
3Management's outlook on competitive pressures.
4Details on patient access initiatives.
5Comments on cost management strategies.